BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30835081)

  • 41. HSP27 knockdown produces synergistic induction of apoptosis by HSP90 and kinase inhibitors in glioblastoma multiforme.
    Belkacemi L; Hebb MO
    Anticancer Res; 2014 Sep; 34(9):4915-27. PubMed ID: 25202074
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increasing the radiation-induced cytotoxicity by silver nanoparticles and docetaxel in prostate cancer cells.
    Hatami Zharabad S; Mohammadian M; Zohdi Aghdam R; Hassanzadeh Dizaj M; Behrouzkia Z
    Mol Biol Rep; 2024 May; 51(1):633. PubMed ID: 38724835
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Co-delivery of paclitaxel and tanespimycin in lipid nanoparticles enhanced anti-gastric-tumor effect in vitro and in vivo.
    Ma L; Yang D; Li Z; Zhang X; Pu L
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):904-911. PubMed ID: 29757014
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation.
    Jeon YK; Park CH; Kim KY; Li YC; Kim J; Kim YA; Paik JH; Park BK; Kim CW; Kim YN
    J Pathol; 2007 Oct; 213(2):170-9. PubMed ID: 17768706
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Folate receptor targeted 17-allylamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric nanoparticles for breast cancer.
    Saxena V; Naguib Y; Hussain MD
    Colloids Surf B Biointerfaces; 2012 Jun; 94():274-80. PubMed ID: 22377218
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level.
    Yu W; Rao Q; Wang M; Tian Z; Lin D; Liu X; Wang J
    Leuk Res; 2006 May; 30(5):575-82. PubMed ID: 16213582
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aryl hydrocarbon receptor is a target of 17-Allylamino-17-demethoxygeldanamycin and enhances its anticancer activity in lung adenocarcinoma cells.
    Chen PH; Chang JT; Li LA; Tsai HT; Shen MY; Lin P
    Mol Pharmacol; 2013 Mar; 83(3):605-12. PubMed ID: 23229511
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
    Francis LK; Alsayed Y; Leleu X; Jia X; Singha UK; Anderson J; Timm M; Ngo H; Lu G; Huston A; Ehrlich LA; Dimmock E; Lentzsch S; Hideshima T; Roodman GD; Anderson KC; Ghobrial IM
    Clin Cancer Res; 2006 Nov; 12(22):6826-35. PubMed ID: 17121904
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of thymidine phosphorylase expression by using an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells.
    Weng SH; Tseng SC; Huang YC; Chen HJ; Lin YW
    Biochem Pharmacol; 2012 Jul; 84(1):126-36. PubMed ID: 22480737
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Transcription inhibition of heat shock proteins: a strategy for combination of 17-allylamino-17-demethoxygeldanamycin and actinomycin d.
    Cervantes-Gomez F; Nimmanapalli R; Gandhi V
    Cancer Res; 2009 May; 69(9):3947-54. PubMed ID: 19383903
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interaction.
    Vasilevskaya IA; Rakitina TV; O'Dwyer PJ
    Cancer Res; 2003 Jun; 63(12):3241-6. PubMed ID: 12810654
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synergistic effect of heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin and X-rays, but not carbon-ion beams, on lethality in human oral squamous cell carcinoma cells.
    Musha A; Yoshida Y; Takahashi T; Ando K; Funayama T; Kobayashi Y; Negishi A; Yokoo S; Nakano T
    J Radiat Res; 2012 Jul; 53(4):545-50. PubMed ID: 22843619
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effective Targeting Survivin, Caspase-3 and MicroRNA-16-1 Expression by Methyl-3-pentyl-6-methoxyprodigiosene Triggers Apoptosis in Colorectal Cancer Stem-Like Cells.
    Sam S; Sam MR; Esmaeillou M; Safaralizadeh R
    Pathol Oncol Res; 2016 Oct; 22(4):715-23. PubMed ID: 27055667
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51.
    Yao Q; Weigel B; Kersey J
    Clin Cancer Res; 2007 Mar; 13(5):1591-600. PubMed ID: 17332306
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.
    Rahmani M; Yu C; Dai Y; Reese E; Ahmed W; Dent P; Grant S
    Cancer Res; 2003 Dec; 63(23):8420-7. PubMed ID: 14679005
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with 17-AAG on glioma cell growth.
    Premkumar DR; Arnold B; Pollack IF
    Mol Carcinog; 2006 May; 45(5):288-301. PubMed ID: 16550610
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of cytotoxicity of a purified venom protein from Naja kaouthia (NKCT1) using gold nanoparticles for targeted delivery to cancer cell.
    Bhowmik T; Saha PP; Sarkar A; Gomes A
    Chem Biol Interact; 2017 Jan; 261():35-49. PubMed ID: 27836789
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models.
    Desale SS; Raja SM; Kim JO; Mohapatra B; Soni KS; Luan H; Williams SH; Bielecki TA; Feng D; Storck M; Band V; Cohen SM; Band H; Bronich TK
    J Control Release; 2015 Jun; 208():59-66. PubMed ID: 25660204
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synergistic effects of rmhTRAIL and 17-AAG on the proliferation and apoptosis of multiple myeloma cells.
    Wang J; Li Y; Sun W; Liu J; Chen W
    Hematology; 2018 Oct; 23(9):620-625. PubMed ID: 29566599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.